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Abstract
Background: Malaria and bacterial infections account for most infectious disease deaths in developing countries. Prompt
treatment saves lives, but rapid deterioration often prevents the use of oral therapies; delays in reaching health facilities
providing parenteral interventions are common. Rapidly and reliably absorbed antimalarial/antibacterial rectal formulations
used in the community could prevent deaths and disabilities. Rectal antimalarial treatments are currently available; rectal
antibacterial treatments are yet to be developed. Assessment of the likely cost-effectiveness of these interventions will
inform research priorities and implementation.
Methods and Findings: The burden of malaria and bacterial infections worldwide and in Sub-Saharan and Southern Africa
(SSA) and South and South-East Asia (SEA) was summarised using published data. The additional healthcare costs (US$) per
death and per Disability Adjusted Life Year (DALY) avoided following pre-referral treatment of severe febrile illness with
rectal antimalarials, antibacterials or combined antimalarial/antibacterials in populations at malaria risk in SSA/SEA were
assessed. 46 million severe malaria and bacterial infections and 5 million deaths occur worldwide each year, mostly in SSA/
SEA. At annual delivery costs of $0.02/capita and 100% coverage, rectal antimalarials ($2 per dose) would avert 240,000
deaths in SSA and 7,000 deaths in SEA at $5 and $177 per DALY avoided, respectively; rectal antibacterials ($2 per dose)
would avert 130,000 deaths in SSA and 27,000 deaths in SEA at $19 and $97 per DALY avoided, respectively. Combined
rectal formulations ($2.50 per dose) would avert 370,000 deaths in SSA and 33,000 deaths in SEA at $8 and $79 per DALY
avoided, respectively, and are a cost-effective alternative to rectal antimalarials or antibacterials alone.
Conclusions: Antimalarial, antibacterial and combined rectal formulations are likely to be cost-effective interventions for
severe febrile illness in the community. Attention should focus on developing effective rectal antibacterials and ensuring
that these lifesaving treatments are used in a cost-effective manner.
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Introduction
Infectious diseases are a leading cause of death in developing
countries. Malaria and bacterial infections account for the
majority of these deaths [1]. Prompt treatment of severe malaria
or sepsis could save lives but clinical deterioration is often rapid,
leading to inability to swallow medicines. The majority of deaths
from febrile illness occur in children in or near home, before these
patients can reach a facility where parenteral treatments can be
provided [2]. Malaria and bacterial infections have overlapping
symptoms [2] and often co-occur with infections such as septicae-
mia, relatively common in children with severe malaria [3,4].
Malaria is also common in children hospitalised with severe
pneumonia in malaria endemic regions [5]. Distinguishing
between malaria, septicaemia and pneumonia is clinically difficult,
particularly in young children. Consequently, as a pragmatic
compromise, the Integrated Management of Childhood Illnesses
(IMCI) strategy developed by WHO and UNICEF recommends
that severely ill febrile children in malaria endemic regions are
treated with parenteral antibiotics and antimalarials [6,7].
Rectal drugs canbe given safely to severe febrile patients, offering
the prospect of providing potentially life-saving pre-referral (i.e.
prior to referral to a healthcare facility) treatment to those who are
seriously ill and are unable to take oral medications reliably. A large
randomised trial of pre-referral community use of rectal artesunate
(Gomes et al. (2009)) [2] showed that in 12,068 malaria patients
unable to take oral treatment in Ghana, Tanzania and Bangladesh,
mortality was halved in those who had not reached hospital within
six hours of rectal artesunate administration.
This paper builds on that finding and considers the economic
case for the development and use of antimalarial, antibacterial and
combined antimalarial/antibacterial rectal interventions for severe
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formulations of antimalarial treatments have already been
developed and are recommended for community use [7,8],
although not yet widely deployed. Rectal formulations of
antibacterial treatment alone or in combination with an
antimalarial are proposed to be developed to target a variety of
bacterial infections. Lower respiratory infections (LRI - mostly
pneumonia [9]) represent the group of bacterial infections with the
largest reported global burden of disease and are the target
bacterial disease of the hypothetical rectal antibacterial component
studied here [1]. There are no significant drug interactions
between parenteral antimalarials and antibiotics [7] so a combined
approach is likely to be safe.
The objectives of this paper are to summarise the incidence and
mortality of severe malaria and severe target bacterial disease both
worldwide and in key regions and to estimate the likely cost-
effectiveness of antimalarial, antibacterial and combined antima-
larial/antibacterial rectal treatments.
Methods
Burden of disease
The burden of malaria and the target bacterial disease was
summarised using published data both globally and for two
specific regions: Sub-Saharan and Southern Africa (SSA - all
countries in Africa except the non-malarious countries in Northern
Africa) and South and South-East Asia (SEA – the malarious
countries from the World Health Organisation (WHO) South-East
Asia (SEARO) and Western Pacific (WPRO) regions). The
presence of malaria in a country was informed by the 2008
World Malaria Report (WMR) [10]. Supplementary Table S1
lists the countries forming the regional groupings. Data are
reported for the under-five (excluding neonates) and five years and
over age groups. Incidence rates are calculated using population
data for 2006 [11,12].
Malaria. The primary source of malaria incidence data was
the 2008 WMR which reports data for ‘fever with parasites’,
encompassing all vectors, for 2006 [10]. Severe malaria is mostly
caused by Plasmodium falciparum [13]. No data sources for the
burden of severe malaria were identified and, therefore, expert
opinion estimates of the percentage of falciparum malaria
incidence in SSA that was severe (5% of all cases in under-fives
and 1% in the remaining population [14,15,16,17]) and the
percentage of falciparum malaria incidence elsewhere that was
severe (2% across all ages) were employed. The proportion of
malaria incidence attributed to falciparum infection at the regional
level is based on the 2008 WHO GBD study [1]. Malaria mortality
data were extracted from the WMR [10].
Target bacterial disease. No single source provided the
data required to estimate the burden of the target bacterial disease.
Pneumonia incidence amongst under-fives was based on a 2006
study of the epidemiology of childhood pneumonia in developing
countries [18,19] that reports incidence of ‘clinical pneumonia’: a
definition consistent with WHO Case Management Guidelines
[20] and IMCI Guidelines [8]. LRI incidence for all ages at the
regional level was informed by the 2008 WHO GBD study [1].
These regional estimates were recalculated to include malarious
countries only.
The proportion of pneumonia cases in under-fives that develop
into severe pneumonia as defined in WHO treatment guidelines
[18,20] (8.6%) is based on Rudan et al. [18]. No equivalent
estimate for those aged five years and over was identified; hence
the same proportion is applied in this population. Our estimates of
target bacterial disease mortality are based on total LRI mortality
for 2004 reported in the 2008 WHO GBD study [1] and
pneumonia mortality in under-fives reported in a 2004 UNICEF
study [21].
Cost-effectiveness
A decision model of the management of severe febrile illness was
developed to evaluate costs, effects and cost-effectiveness of rectal
treatments for people with severe febrile illness in populations at
risk of malaria in SSA and SEA. While the whole SSA region is at
risk of malaria, SEA is characterised by a mixed malaria risk
profile, with areas of stable, unstable and no malaria risk. A recent
study suggested that 45% of the SEA population is at risk of
malaria [22]. We therefore assume that 45% of the target severe
bacterial disease in SEA occurs in this population and the cost-
effectiveness results we present are specific to this population.
The model evaluates the population health effects and costs of
the current usual treatment practice, with no widespread use of
pre-referral rectal treatment for malaria, as well as of three further
health policies: (1) rectal antimalarial added to usual practice; (2)
rectal antibacterial added to usual practice, and (3) a combined
antimalarial/antibacterial rectal formulation added to usual
practice (Figure 1). All model parameters are detailed in
Table 1. In the model, patients with severe malaria or severe
bacterial disease either attend a medical facility with the capacity
to deliver parenteral treatment within 6 hours (from timing of
rectal intervention administration), attend such care after 6 hours,
or do not attend such care. These access-to-treatment categories
reflect the treatment effects of rectal artesunate reported in Gomes
et al. [2]. Access rates achieved in that study were high due to
incentives provided within the study, and are unlikely to reflect
usual practice; hence lower access rates are used in the decision
model (Table 1, see also supplementary material). In the base case
analysis the proportion of severe febrile cases who access health
care is assumed to be unaffected by the use of rectal treatment.
In the model, the case fatality rate for severe malaria patients
who do not reach a health care facility with the capacity to deliver
parenteral treatment was set to 50% (for patients five years and
older) and 35% (for under-fives), based on expert opinion in a
Tanzanian setting [23]. The case fatality rate for severe bacterial
disease patients who do not access such care was set to 16% (all
ages), based on an expert opinion [24] informed by a study in
children with severe LRI [18,24,25]. Patients with severe malaria
or bacterial disease who reach an appropriate health care facility
were assumed to receive first-line treatment as appropriate,
following clinical diagnosis. First-line treatment for severe malaria
in SSA is still predominantly parenteral quinine, although this is
likely to change soon to artesunate [26]; in SEA artemether is also
widely used [10]. Treatment failure rates were set at 26% (five
years and over) and 6% (under-five), based on a study of
parenteral treatment for severe malaria in hospitalised Asian
patients [27,28]. First-line treatment for severe bacterial disease
was assumed to be benzylpenicillin as recommended by WHO
[9,20]. First-line treatment failure rates were set at 9.8% (five years
and over) and 5.8% (under-fives) [29,30]. For both diseases,
treatment failure rates were adjusted for patients who accessed
healthcare within 6 hours of, and more than 6 hours after rectal
intervention administration, using the ratio of respective mortality
rates reported in Gomes et al. [2]. Following first-line treatment,
patients either improve and undertake oral therapy, or deteriorate
and die. Some patients with severe malaria recover but with
permanent neurological sequelae and the incidence rate for such
sequelae was set to 5% [2,26,31,32].
Full coverage of the rectal interventions within relevant target
populations was assumed in order to generate estimates of the
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patients who receive the rectal formulation will have a disease that
is neither malaria nor the target bacterial disease (a ‘spillout’
population). Disease management was not modelled for these
patients (as no effects of the rectal formulation are expected), but
the decision model captures the cost of the rectal intervention. The
percentage of severe febrile patients treated with a rectal
antimalarial who do not have malaria was set at 26%, based on
data from Gomes et al. [2]. The percentage of severe febrile
patients treated with a rectal antibacterial who do not have the
target bacterial disease, and the percentage of severe febrile
patients treated with a combined rectal formulation who have
neither severe malaria nor target bacterial disease, were both
assumed to be 10%.
In Gomes et al. rectal antimalarial treatment reduced mortality
by 51% in malaria patients who were alive but not in hospital
within 6 hours of treatment administration [2]. Gomes et al.
reported no effect in participants who present at hospital prior to
six hours: our model applies this finding. A 20% reduction in the
case fatality rate of malaria was applied in those who did not
attend hospital at all. Although Gomes et al. reported a reduction
of 85% in long-term neurological sequelae [2], no effect was
reported in two other studies [26,33], hence a mid-point value of
42% was applied. Rectal antibacterial treatment was assumed to
reduce mortality in severe target bacterial disease patients who are
alive but not in hospital within 6 hours of treatment administra-
tion by 20%, and in such patients who did not attend hospital by
10%; no effect in such patients reaching appropriate healthcare
within six hours was modelled. These values were assumptions
based on estimates of parenteral antibiotic treatment effects
adjusted downwards to reflect uncertainty concerning adequate
rectal absorption. The effect of the combined rectal formulation
was modelled by adding the treatment effects of both individual
interventions.
All costs were calculated in US dollars for 2005, adjusted for
inflation [34]. End user costs of $2.00 and $2.50, comparable with
the cost of parenteral antimalarial treatment for under-fives, were
used for the antimalarial or antibacterial rectal formulations, and
the combined rectal formulation, respectively. The perspective of a
healthcare provider was taken, hence the analysis was limited to
Figure 1. Schematic of the decision model of the management of severely ill febrile patients. Figure 1 illustrates the typical disease
management of severe febrile patients in populations at risk of malaria in SSA and SEA, for each of the four scenarios of interest: usual practice; usual
practice with antimalarial rectal treatment; usual practice with antibacterial treatment, and usual practice with combined antimalarial/antibacterial
rectal treatment. ‘Hospital’ refers to a medical establishment able to provide parenteral and supportive treatment for a severe febrile patient. Pathway
A = access to treatment for severe malaria or target bacterial disease. Usual practice refers to a situation where no rectal treatments for severe febrile
illness are widely used. Tables 1 and 2 contain details of all the parameters used within the model, for each region, including access to care rates,
treatment effects and burden of disease.
doi:10.1371/journal.pone.0014446.g001
CEA of Rectal AM/AB in Tropics
PLoS ONE | www.plosone.org 3 December 2010 | Volume 5 | Issue 12 | e14446Table 1. Parameters in the cost-effectiveness decision model for severe febrile illness.
Parameter Base case value
Values for sensitivity
and scenario analysis
Data sources for
base case/
sensitivity and
scenario analysis
Percent of cases that – access hospital or die within 6 hours/access hospital after 6 hours/never access hospital
SSA (Values for sensitivity analysis: lower access - higher access) 40%/40%/20% 15%/55%/30% -
55%/32%/13%
1
Asmp/Asmp/[2]
SEA (Values for sensitivity analysis: lower access – higher access) 80%/13%/7% 40%/40%/20% -
93%/5%/2%
1
Asmp/Asmp/[2]
Disease and treatment related parameters – severe malaria
% of incidence that is severe disease (SSA) – under-fives/five years and over 5%/1% 2.5–7.5%/0.5–1.5%
2 [14,15,16,17]
% of falciparum malaria incidence that is severe disease (SEA) – all ages 2% 1–3% Asmp [28]
Untreated case fatality rate – under-fives/five years and over 30%/50% 15–45%/25–75% [23]
First-line treatment failure rate – under-fives/five years and over 6%/26% 3%/13%
3 [27,28]/[2]
Neurological sequelae incidence rate – all ages 5% 2.5–7.5%
2 Asmp [2,26,31,32]
Disease and treatment related parameters – severe bacterial disease
% of all incidence that is severe disease - all ages 8.6% 4.3–12.9%
2 [18]
Untreated case fatality rate – all ages 16% 8–24% [18,24]
First-line treatment failure rate – under-fives/five years and over 5.8%/9.8% - [29,30]
Neurological sequelae incidence rate – all ages 0% - Asmp
Rectal treatment effects – severe malaria
Reduction in mortality for patients who are alive but not in hospital
within 6 hours of rectal treatment administration (RR)
51% 23–68%
4 [2]/[2]
Reduction in neurological sequelae in all patients (RR) 42% 0–85%
5 Midpoint [2,33]/[2,33]
Reduction in the untreated case fatality rate (RR) 20% 10–30%
2 Asmp
Rectal treatment effects – severe bacterial disease
Reduction in mortality for patients who are alive but not in hospital
within 6 hours of rectal treatment administration
20% 10–30%
2 Asmp
Reduction in the untreated case fatality rate 10% 5–15%
2 Asmp
Percentage of all patients treated with rectal formulations who do not have the target disease(s) and will not benefit from treatment
Antimalarial only/Antibacterial only/Combined 26%/10%/10% - [2]/Asmp/Asmp
Costs (US dollars, 2005) – under-fives/five years and over
First-line parenteral antimalarial treatment – quinine
6 $2.22/$9.68 - [10], [35]
First-line parenteral antimalarial treatment – artemether
6 $3.22/$14.05 - [10], [35]
Oral antimalarial treatment – chloroquine and primaquine
7 $0.32/$1.39 - [10], [35]
Oral antimalarial treatment – artesunate and amodiaquine
7 $0.27/$0.80 - [10], [35]
Oral antimalarial treatment – artemether-lumefantrine
7 $0.93/$2.79 - [10], [35]
First-line antibiotic treatment – benzylpenicillin $0.31/$2.06 -[ 3 6 ]
Oral antibiotic treatment – amoxicillin $0.22/$0.84 -[ 3 6 ]
Antimalarial only rectal formulation - all ages $2.00 $1.00–3.00
2 Asmp
Combined rectal formulation - all ages $2.50 $1.25–3.75
2 Asmp
Antibacterial only rectal formulation - all ages $2.00 $1.00–3.00
2 Asmp
Rapid diagnostic test for malaria $0.83 -[ 3 5 ]
Cost per inpatient day at secondary level hospital in SSA $25.17 $12.58–37.75
2 [38]
Cost per inpatient day at secondary level hospital in SEA $25.80 $12.90–38.70
2 [38]
Other parameters
Average length of stay (days) for patients who survive/survive
with neurological sequelae/die
4.5/10/2 - [14]/[39]/[14]
Life expectancy conditional on survival Region-specific
life tables
8
Japanese
life tables
8
[44] [58]
Discount rate for future life years 3% - [1]
Disability weight for malaria patients with long-term neurological sequelae 0.471 - [1]
CEA of Rectal AM/AB in Tropics
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reflected a full treatment course and were based on WHO and
Kenyan price lists [35,36]. The cost of oral antibiotics was based
on the use of amoxicillin [9,37]. Dosages reflected WHO
treatment guidelines [9,20]. The cost of a rapid diagnostic test is
included in the model as a proxy cost for any diagnostic or co-
treatment in addition to appropriate first line therapy [35].
However treatment decisions were not affected by the use of
diagnostics. Hospitalisation costs were evaluated using data on cost
per day in hospital [38] and duration of hospital admission
[14,39]. The likely cost of deploying rectal treatments was
informed by three studies evaluating interventions in communities
in developing countries [40,41,42]. These studies estimated
delivery costs to be $0.03, $0.01, and $0.09 per capita, respectively.
A value of $0.02 per capita was used in the base case analysis to
reflect all intervention delivery costs (i.e. recruitment and training
of providers and education of population) except for drug costs. It
was also assumed that delivery mechanisms for an antimalarial,
antibacterial and the combined formulations would be similar and
therefore their delivery costs per capita would not differ.
Disability Adjusted Life Years (DALYs) were calculated using
standard methods [43] without age weighting. Region-specific life
tables were used to estimate life expectancy conditional on survival
[44] with future life years discounted at 3%. A disability weight of
0.471 was applied for malaria patients surviving with neurological
sequelae [45].
Additional costs per death and DALY averted are presented for
populations at risk of malaria in SSA and SEA, separately for (1)
rectal antimalarial treatment compared with usual practice; (2) rectal
antibacterial treatment compared with usual practice; (3) combined
antimalarial/antibacterial rectal formulation compared with usual
practice; (4) combined antimalarial/antibacterial rectal formulation
compared with rectal antimalarial, and (5) combined antimalarial/
antibacterial rectal formulation compared with rectal antibacterial.
Sensitivity analyses. One-way sensitivity analyses were
conducted for key parameters across all comparisons including:
hospitalisation and rectal treatment costs; disease incidence rates;
neurological sequelae incidence rates; untreated case fatality rates;
the treatment effect of the rectal formulations on mortality and
long-term disability; and the life tables used within the DALY
calculations (Table 1).
Variations in access to care were also considered. Access rates
from Gomes et al. [2] were firstly applied both in usual care and
following rectal treatment, and then applied only after rectal
treatment. A scenario of lower access rates, both in usual care and
following rectal treatment was also considered.
The combined impact of variationsin delivery costs and coverage
was also evaluated. For delivery costs, a range between zero and
$0.10 was considered [40,41,42], given the uncertainty over the
delivery mode and likely variations in different settings. Coverage
levels may also vary, dependent on how interventions are
implemented, hence coverage was varied between 100% and 50%.
Further details concerning alternative parameter values and
data sources are available in the supplementary material (Text
S1).
As this study was based on published information and involved
no individual participants’ data, ethics approval was not required.
Results
Burden of disease
Malaria. Worldwide incidence of falciparum malaria was
estimated at 247 million cases in 2006 (Table 2), 241 million of
which occurred in SSAand SEA[10].Falciparummalaria represents
88% of all malaria worldwide: 94% in SSA and 57% in SEA[1]. The
total number of severe malaria cases was estimated at 7.2 million in
2006: 6.9 million in SSA and 0.3 million in SEA. Global mortality
was estimated to be 881,000 in 2006 [10]: 837,000 deaths occurred in
SSA, 736,000 of those in under-fives. Of 40,000 malaria deaths in
SEA, 26,000 were in those aged five years and over.
Target bacterial disease. The annual global incidence of
LRI was estimated at 447 million cases, with 156 million
pneumonia cases in under-fives [1,19] (Table 2). There were
around three times as many episodes per person per year overall in
SSA as compared to SEA. The pattern of severe disease followed
that of overall incidence, with 11 million cases in SSA and 17
million in SEA [1,19]. Annual global mortality from LRI was
estimated at 4.2 million deaths, with 1.5 million in SSA (including
1 million pneumonia deaths in under-fives) and 1.7 million in SEA
(including 0.6 million pneumonia deaths in under-fives) [1,21].
The combined burden of malaria and target bacterial
disease. The combined burden of severe malaria and target
bacterial disease was estimated at 46 million cases annually
worldwide: 18 million in SSA and 17 million in SEA (Table 2). 5
million deaths worldwide were estimated to occur each year across
all age groups, 2.3 million of these in SSA and 1.8 million in SEA.
Alternative estimates of the burden of severe febrile illness are
summarised in the supplementary material (Text S1).
Cost-effectiveness analysis
The cost-effectiveness results are reported in Table 3.
Rectal antimalarial treatment versus usual practice.
Compared to usual practice, full coverage with rectal
antimalarials would avoid 238,428 deaths in SSA and 6,873
deaths in SEA annually at added healthcare costs of $35 million in
SSA and $30 million in SEA. The cost per death avoided is $148
in SSA and $4,429 in SEA, with a cost per DALY averted of $5i n
SSA and $177 in SEA.
RR=risk ratio; Asmp=Assumption; SSA-Sub Saharan and Southern Africa, SEA-South and South-East Asia;
1Rates of access reported in Gomes et al. [2];
2Parameter values varied by 50% above and below the base case value;
3Parameter values varied by 50% below the base case value only, to reflect lower treatment failure rates in Gomes et al. [2];
495% confidence interval reported in Gomes et al.[ 2 ] ;
5Parameter values varied between estimates reported in the two sources;
6Artemether is used alongside quinine in SEA, hence the cost of first-line parenteral antimalarial treatment in this region was assumed to be an average of the cost of
quinine treatment and artemether treatment [10];
7National policies for treatment of uncomplicated falciparum malaria vary by country, Average costs were calculated for each region based on region-wide antimalarial
drug policy as reported in the 2008 WMR [10];
8Region-specific life tables were used to estimate life expectancy conditional on survival. Japanese life tables were used within a sensitivity analysis.
doi:10.1371/journal.pone.0014446.t001
Table 1. Cont.
CEA of Rectal AM/AB in Tropics
PLoS ONE | www.plosone.org 5 December 2010 | Volume 5 | Issue 12 | e14446Rectal antibacterial treatment versus usual practice.
Compared to usual practice, full coverage with rectal antibacterial
treatment would avoid 129,263 deaths in SSA and 26,524 deaths in
SEA annually, at added healthcare costs of $4 7mi ll i o ni ne a c ho fSS A
and SEA. The cost per death avoided is $360 in SSA and $1,789 in
SEA, with a cost per DALY averted of $19 in SSA and $97 in SEA.
Combined antimalarial/antibacterial rectal formulation
versus usual practice. Compared to usual practice (with rectal
antimalarial or antibacterial treatment not in widespread use), a
combined rectal formulation would avoid 367,691 deaths in SSA
and 33,397 deaths in SEA annually at added healthcare costs of
$73 million in SSA and $53 million in SEA. The cost per death
avoided is $200 in SSA and $1,574 in SEA, with a cost per DALY
averted of $8 in SSA and $79 in SEA.
Combined antimalarial/antibacterial rectal formulation
versus antimalarial only rectal treatment. Compared to a
scenario where rectal antimalarial treatment is already in use, a
combined rectal formulation would avoid a further 129,263 deaths
in SSA and 26,524 deaths in SEA annually at added healthcare
costs of $38 million in SSA and $22 million in SEA. The cost per
Table 2. Annual burden of malaria and target bacterial disease.
Malaria Population World SSA
2 SEA
2 [Source] Data year
Incidence, thousands
(Episodes per person per year)
Under five years 121,495 (0.194) 117,774 (0.926) 2,148 (0.008) [10] 2006
Five years and over 125,077 (0.021) 100,213 (0.158) 21,351 (0.007) [10] 2006
TOTAL 246,572 (0.037) 217,988 (0.286) 23,499 (0.007) [10] 2006
Severe cases, thousands
(Episodes per person per year)
1
Under five years 5,930 (0.009) 5,889 (0.046)2 5 ( 0.0001) [10,14] 2006
Five years and over 1,280 (0.0002) 1,002 (0.002)2 4 5 ( 0.0001) [10,14] 2006
TOTAL 7,211 (0.001) 6,891 (0.009) 269 (0.0001) [10,14] 2006
Mortality, thousands
(Deaths per 1,000 incident cases)
Under five years 751 (6.185) 736 (6.245)1 4 ( 6.587) [10] 2006
Five years and over 130 (1.037) 101 (1.007)2 6 ( 1.199) [10] 2006
TOTAL 881 (3.574) 837 (3.837)4 0 ( 1.691) [10] 2006
Target bacterial disease
Incidence, thousands
(Episodes per person per year)
Under five years 155,686 (0.248) 37,006 (0.291) 89,681 (0.325) [19] 2006
Five years and over 291,128 (0.049) 95,825 (0.151) 103,018 (0.034) Residual
TOTAL 446,814 (0.068) 132,831 (0.174) 192,700 (0.059) Calculated based
on [1,19] 2004, 2006
Severe cases, thousands
(Episodes per person per year)
Under five years 13,389 (0.021) 3,183 (0.025) 7,713 (0.028) [19] 2006
Five years and over 25,037 (0.004) 8,241 (0.013) 8,860 (0.003) Residual
TOTAL 38,426 (0.006) 11,423 (0.015) 16,572 (0.005) Calculated based
on [1,19] 2004, 2006
Mortality, thousands
(Deaths per 1,000 incident cases)
Under five years 2,044 (13.129) 1,047 (28.292)6 2 7 ( 6.991) [21] 2004
Five years and over 2,133 (7.325) 407 (4.243) 1,113 (10.799) Residual
TOTAL 4,177 (9.348) 1,454 (10.943) 1,740 (9.027) [1] 2004
Malaria and target bacterial disease
Incidence, thousands
(Episodes per person per year)
Under five years 277,181 (0.442) 154,781 (1.217) 91,830 (0.333) Calculated
Five years and over 416,205 (0.070) 196,038 (0.308) 124,369 (0.042) Calculated
TOTAL 693,387 (0.105) 350,819 (0.460) 216,199 (0.066) Calculated
Severe cases, thousands
(Episodes per person per year)
Under five years 19,319 (0.031) 9,071 (0.071) 7,737 (0.028) Calculated
Five years and over 26,318 (0.004) 9,243 (0.015) 9,104 (0.003) Calculated
TOTAL 45,637 (0.007) 18,314 (0.024) 16,842 (0.005) Calculated
Mortality, thousands
(Deaths per 1,000 incident cases)
Under five years 2,795 (10.085) 1,783 (11.517)6 4 1 ( 6.982) Calculated
Five years and over 2,262 (5.436) 508 (2.589) 1,138 (9.151) Calculated
TOTAL 5,058 (7.294) 2,290 (6.528) 1,779 (8.230) Calculated
SSA-Sub Saharan and Southern Africa, SEA-South and South-East Asia.
1The burden of severe malaria in SSA was calculated by applying expert opinion estimates of the percentage of total incidence in SSA that was severe to the entire
malaria incidence. In all other regions, expert opinion estimates of the percentage of falciparum malaria incidence that was severe were applied.
2Malaria rates presented for total population. It should be noted that 55% of the population in SEA is not at risk of malaria.
doi:10.1371/journal.pone.0014446.t002
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DALY averted of $15 in SSA and $45 in SEA.
Combined antimalarial/antibacterial rectal formulation
versus antibacterial only rectal treatment. Compared to a
scenario where rectal antibacterial treatment is already in use, a
combined rectal formulation would avoid a further 238,428 deaths
in SSA and 6,873 deaths in SEA at added healthcare costs of $27
million in SSA and $5 million in SEA. The cost per death avoided
is $113 in SSA and $743 in SEA, with a cost per DALY averted of
$4 in SSA and $30 in SEA.
Cost-effectiveness results for an antibacterial only intervention
in populations not at risk of malaria in SEA are presented in the
supplementary material (Text S2).
Sensitivity and scenario analyses
Figure 2 summarises the sensitivity analyses for the compar-
isons of each rectal intervention versus usual practice. Additional
details for all parameter variations and comparisons are reported
in Table S2. All comparisons were moderately sensitive to
variations in the cost of the rectal formulation. For the comparison
between a combined rectal formulation and usual practice, a 50%
reduction in the price of rectal treatment reduced the cost per
DALY averted from $8t o$5 in SSA and from $79 to $63 in SEA.
Incremental cost-effectiveness estimates were also sensitive to the
rectal antibacterial treatment effect. When a smaller treatment
effect was applied (10% reduction in mortality in patients alive but
not in hospital within 6 hours of rectal treatment administration;
Table 3. Cost-effectiveness results.
Comparison Population SSA
1 SEA
1
Additional
cost
(‘000 US $)
Deaths averted/
DALYs averted
Cost per
death averted/
Cost per DALY
averted
(US $)
Additional
cost
(‘000 US $)
Deaths
averted/
DALYs
averted
Cost per
death averted/
Cost per DALY
averted
(US $)
(1) Rectal antimala-
rial treatment versus
usual practice
2
Under five
years
16,990 156,131/
4,929,402
109/
3
2,556 220/
7,427
11,641/
344
Five years
and over
18,282 82,297/
1,516,042
222/
12
27,883 6,654/
164,134
4,191/
170
Total 35,272 238,428/
6,445,443
148/
5
30,439 6,873/
171,560
4,429/
177
(2) Rectal antibacte-
rial treatment versus
usual practice
2
Under five
years
10,708 27,485/
753,301
390/
14
10,667 10,089/
297,756
1,057/
36
Five years
and over
35,839 101,778/
1,684,796
352/
21
36,787 16,435/
193,419
2,238/
190
Total 46,547 129,263/
2,438,097
360/
19
47,454 26,524/
491,174
1,789/
97
(3) Combined antimala-
rial and antibacterial
rectal formulation
versus usual practice
2
Under five
years
27,349 183,616/
5,682,703
149/
5
12,671 10,308/
305,183
1,229/
42
Five years
and over
46,054 184,075/
3,200,837
250/
14
39,889 23,089/
357,552
1,728/
112
Total 73,403 367,691/
8,883,540
200/
8
52,560 33,397/
662,735
1,574/
79
(4) Combined antimalarial
and antibacterial rectal
formulation versus rectal
antimalarial treatment
Under five
years
10,359 27,485/
753,301
377/
14
10,115 10,089/
297,756
1,003/
34
Five years
and over
27,772 101,778/
1,684,796
273/
16
12,007 16,435/
193,419
731/
62
Total 38,131 129,263/
2,438,097
295/
15
22,122 26,524/
491,174
834/
45
(5) Combined antimalarial
and antibacterial rectal
formulation versus rectal
antibacterial treatment
Under five
years
16,641 156,131/
4,929,402
107/
3
2,004 220/
7,427
9,127/
270
Five years
and over
10,214 82,297/
1,516,042
124/
7
3,103 6,654/
164,134
466/
19
Total 26,856 238,428/
6,445,443
113/
4
5,107 6,873/
171,560
743/
30
SSA-Sub Saharan and Southern Africa, SEA-South and South-East Asia.
1These cost-effectiveness results are for the whole region in SSA, and for populations at risk of malaria only in SEA;
2Usual practice refers to a situation where no rectal treatments for severe febrile illness are widely used.
doi:10.1371/journal.pone.0014446.t003
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averted for the comparison between an antibacterial only
intervention and usual practice increased from $19 to $36 in
SSA and from $97 to $191 in SEA. Variations in the rectal
antimalarial treatment effect had a similar although slightly
reduced impact on cost-effectiveness.
The largest changes in incremental cost-effectiveness were
observed when healthcare access rates were varied. When higher
access rates were applied both before and after rectal treatment
introduction in SEA (see Table 1)t h ec o s tp e rD A L Ya v e r t e d
increased from $79 to $232 (combined rectalformulation versus usual
practice). Applying higher access rates only after rectal formulation
introduction had a notable effect on the comparison between a
combined rectal formulation and an antimalarial only rectal
formulation in SSA, increasing the cost per DALY averted from
$16 to $32: this occurs because more patients benefit from rectal
treatment but hospitalisation costs increase substantially. Conversely,
when we considered a scenario with lower access rates applied both
before and after rectal treatment introduction, the cost per DALY
averted decreased for all comparisons in both SSA and SEA.
The impact of delivery costs and intervention coverage on the
cost-effectiveness results are illustrated in Figure 3 (Table S3
provides further detail). In SSA, the cost per DALY averted
remained under $100 for all combinations of delivery cost and
coverage level considered, for all comparisons. For populations at
risk of malaria in SEA there was more variation. With delivery
costs of $0.10 per capita and 50% coverage, the cost per DALY
averted for the comparison between the combined formulation
and current practice increased from $79 to $481.
Discussion
The total annual burden of severe malaria and severe target
bacterial disease is enormous, with 2.3 million related deaths
occurring in SSA and 1.8 million in SEA, although considerable
uncertainty surrounds mortality in some remote but populous
areas within SEA such as North-east India, Myanmar and
Indonesia [46,47,48,49]. Emergency pre-referral rectal antimalar-
ial treatment for severe malaria is already available and is
incorporated in the WHO treatment guidelines [7], although not
yet widely deployed. Antibacterial and combined antimalarial/
antibacterial rectal formulations have been proposed to be
developed which, if safe, effective and acceptable, could be added
to current treatment guidelines. Ensuring rapid, adequate and
reliable rectal absorption is a key development objective. This
paper uses current disease estimates and costs to suggest that these
pre-referral interventions would reduce considerably the burden of
severe febrile illnesses in SSA and SEA in a cost-effective manner.
For all comparisons, the incremental cost-effectiveness ratios in
SSA were in the range of ‘highly attractive’ interventions ($25 per
DALY averted) under World Bank guidance [50,51], while the
ratios in SEA were generally in the range of ‘attractive’
interventions ($150 per DALY averted), under the same guidance.
In addition, our results compared favourably with another
benchmark for cost-effectiveness, the gross domestic product per
capita in the respective countries [52,53], as well as cost-
effectiveness estimates for other interventions for malaria and
bacterial infections [54,55,56].
This work has a number of potential limitations. First, the
burden of disease estimates combine data from several sources;
treatment effects and costs were also based on multiple sources
from different geographical locations. Ideally, this work would be
based on epidemiological and economic data originating from the
same population but this has not been possible in our case as two
of the intervention studies are not yet developed and no
deployment study of antimalarial suppository is yet publically
available. Second, whereas treatment effects for antimalarials have
been relatively well defined, the effects of antibiotics have not
been, and there is considerable uncertainty over both the rate and
magnitude of their potentially lifesaving benefit. Third, the
categories of access to care used in the decision model were
selected to align with the treatment effects of the antimalarial
component of the rectal formulation. The time course of illness for
patients with severe bacterial infections might however differ, and
studies of rectal antibacterial treatment efficacy and effectiveness
are needed. Fourth, the effectiveness of rectal treatment may also
vary in different population groups due to the presence of
underlying conditions. For example, the potential for antibacterial
treatment to impact on mortality may be limited in people who
develop severe pneumonia alongside existing immunocompromis-
ing conditions such as HIV infection [57]. Fifth, the analysis does
not consider the impact of these rectal formulations on the
emergence or spread of resistance to the active components. Sixth,
wider household costs related to seeking treatment and living with
long-term sequelae are likely to be significant, particularly if rectal
treatments increase the use of health services. Finally, the likely
delivery costs, end-user costs and coverage levels of the rectal
interventions are unclear. These parameters are likely to depend
on intervention implementation and to vary geographically.
Further work to study the most cost-effective delivery systems
locally is needed.
We have explored the impact of changes in important factors on
cost-effectiveness. A reduction in the burden of severe febrile
illness due to improved availability of other treatments (for
example, as a result of the ACT subsidy scheme, or vaccine
development) would reduce the cost-effectiveness of rectal
treatments, unless delivery costs were substantially lowered (for
example, through improved targeting of interventions). Urbanisa-
tion might bring people closer to health facilities, and appropriate
interventions at these facilities might reduce the need for rectal
treatment. Nonetheless, these separate developments are unlikely
to alleviate the need for lifesaving interventions and, as our
sensitivity analyses suggest, the interventions remain in the range
of cost-effective interventions even under somewhat large changes
in the parameters affected.
The cost-effectiveness analyses reported in this paper suggest
that rectal formulations of an antibacterial and/or an antimalarial
are likely to be cost-effective pre-referral interventions for severe
febrile illness in the community. Future work is needed to develop
the rectal antibacterial interventions and to study the best ways to
Figure 2. Sensitivity analysis of cost-effectiveness (US$/DALY averted) of rectal formulations for severe febrile illness. Figure 2
presents the impact of changes in values of different parameters on cost-effectiveness results. The three panels present these analyses for rectal
antimalarial treatment compared with usual practice (Panel A), rectal antibacterial treatment compared with usual practice (Panel B), and a
combined antimalarial/antibacterial rectal formulation compared with usual practice (Panel C). Comparisons between a combined antimalarial/
antibacterial rectal formulation and either rectal antimalarial or rectal antibacterial treatment are not presented, however these analyses are reported
in Table S2. Usual practice refers to a situation where no rectal treatments for severe febrile illness are widely used. Base case estimates of cost per
DALY averted are indicated by a red line for each comparison and region. * For full details of parameter variations, see Table 1 and supplementary
Table S2.
doi:10.1371/journal.pone.0014446.g002
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illustrates how both changes in the cost of deploying rectal treatments (per capita), as well as the coverage levels achieved, could impact on the cost-
effectiveness of these interventions. The three panels present these analyses for rectal antimalarial treatment compared with usual practice
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in the communities that need them.
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of severe febrile illness are provided for two regions, Sub-Saharan
and Southern Africa (SSA), and South and South East Asia (SEA),
alongside worldwide figures. The SSA region contains all African
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Libya, Morocco and Tunisia), where malaria is not present [World
Health Organisation (2008) World Malaria Report]. Five
countries were excluded due to a lack of data (Djibouti, Mauritius,
Mayotte, Seychelles and Lesotho). The SEA region contains all the
countries from two World Health Organisation (WHO) regions:
SEARO (South East Asian Regional Office of the WHO) and
WPRO (Western Pacific Regional Office of the WHO) which are
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Report [World Health Organisation (2008) World Malaria
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